OxyContin OP 80mg β The Complete Medical Guide
Introduction to OxyContin OP 80mg
OxyContin OP 80mg is anΒ abuse-deterrent, extended-release oxycodone formulationΒ classified as aΒ Schedule II controlled substance. This maximum-strength tablet is reserved forΒ management of severe, around-the-clock pain in opioid-tolerant patients. The “OP” designation indicates it containsΒ physical and chemical barriersΒ to deter crushing, snorting, or injecting – though risks of misuse and addiction remain significant.
Percocet 10-325mg
Percocet 10-325mg is a combination prescription medication used to manage moderate to severe pain. It contains 10 mg of oxycodone, a powerful opioid, and 325mg of acetaminophen, a pain reliever that enhances the effects of oxycodone. This formulation provides effective pain relief for conditions such as post-surgical pain, injury, or chronic pain. Due to its opioid content, Percocet 10-325 mg should be used strictly as prescribed to avoid the risks of misuse, addiction, and overdose. Always follow your healthcare providerβs instructions for safe and effective pain management.
Medical Uses & Indications
FDA-Approved Uses
β
Β Severe chronic painΒ requiring continuous opioid therapy
β
Β Cancer pain managementΒ in highly opioid-tolerant patients
β
Β Pain uncontrolled by lower-dose opioids
Key Clinical Features
β’Β Formulation:Β Abuse-deterrent extended-release
β’Β Onset:Β 1-2 hours
β’Β Duration:Β 12-hour controlled release
β’Β Equianalgesic ratio:Β 80mg q12h β 120mg oral morphine daily
β’Β DEA Classification:Β Schedule II (Highest abuse potential)
Pharmacology & Mechanism
Neurochemical Action
β’ Full ΞΌ-opioid receptor agonist
β’ ΞΊ-opioid receptor partial agonist
β’ Sustained activation of pain modulation pathways
Abuse-Deterrent Properties
β’Β Hard plastic coatingΒ resists crushing
β’Β Viscous gel formationΒ when dissolved
β’Β Not completely abuse-proofΒ (oral abuse still possible)
Dosing & Administration
Strict Eligibility Criteria
β’Β Confirmed opioid tolerance:Β β₯160mg oral morphine equivalent daily
β’Β Stable pain patternΒ (Not episodic/breakthrough)
β’Β Failed trials of lower-dose opioids
Conversion Protocol
-
Calculate total daily morphine equivalent
-
Reduce by 25-50% (incomplete cross-tolerance)
-
Divide by 2 for q12h dosing
Critical Safety Notes
β Β Hospital initiation mandatory
β Β Must swallow wholeΒ (never cut/crush/chew)
β Β Requires dual prescriber verification
β Β Naloxone rescue kit mandatory
Safety Profile
Common Adverse Effects
β’ Severe constipation (universal)
β’ Nausea/vomiting (50-60%)
β’ Profound sedation
β’ Cognitive impairment
Black Box Warnings
βΒ High potential for addiction and abuse
βΒ Life-threatening respiratory depression
βΒ Accidental ingestion can be fatal
βΒ Concomitant CNS depressant danger
Risk Mitigation Strategies
Prescribing Safeguards
-
Specialist pain management consultationΒ required
-
Triplicate prescription formsΒ in most states
-
Weekly follow-upsΒ for first 3 months
-
Random pill counts and UDS
Patient Safety Measures
β’Β Biometric locked storageΒ required
β’Β Mandatory caregiver training
β’Β Medication disposal systemΒ provided
β’Β Absolute alcohol prohibition
Clinical Alternatives
For Severe Chronic Pain
β’Β Xtampza ER (abuse-deterrent oxycodone)
β’Β MethadoneΒ (For select patients)
β’Β Fentanyl transdermal
Non-Opioid Options
β’Β Intrathecal pump therapy
β’Β Dorsal column stimulation
β’Β Adjuvant medications
Special Population Considerations
| Population | Consideration | Action |
|---|---|---|
| Elderly (β₯65) | CONTRAINDICATED | – |
| Hepatic impairment | CONTRAINDICATED | – |
| Renal (CrCl<30) | CONTRAINDICATED | – |
| Pediatric | CONTRAINDICATED | – |
Reviews
There are no reviews yet.